FDA Oks Checkpoint Therapeutics’ UNLOXCYT For Advanced Cutaneous Squamous Cell Carcinoma treatment
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Checkpoint Therapeutics Inc. (CKPT) announced that the U.S. Food and Drug Administration (FDA) has approved UNLOXCYT(cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1363872209-a5ec723c281747b380b15386db71cb58.jpg "Here’s The Average Net Worth of Each Class: How Does Yours Compare?")
:max_bytes(150000):strip_icc():format(jpeg)/severancepay.asp-final-32f0096580d6489aa78ad87a2dc84e6a.png "7 Considerations When You Negotiate Severance")
:max_bytes(150000):strip_icc():format(jpeg)/what-is-a-hedge-fund-597e47839abed50010bcdeb1.jpg "8 Hedge Fund Manager Startup Tips")